Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
-
REGULATORY May Listing OK’ed for Darzquro, Pemazyre, Vitrakvi, Kesimpta and More
May 12, 2021
-
REGULATORY Ultomiris Faces 4.3% Price Cut under CEA Scheme
May 12, 2021
-
REGULATORY Tecentriq, 3 I/O Rivals Face Quarterly Re-Pricing; Price Cuts Yet Again for Opdivo, Keytruda
May 11, 2021
-
BUSINESS Takeda Submits Positive Japan Data for Approval-Pending Moderna Vaccine
May 11, 2021
-
BUSINESS Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
-
ORGANIZATION JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
-
BUSINESS Kyoto Startup to Begin Clinical Trial of iPSC-Derived Platelet Agent This Year, Eyes 10 Billion Yen Biz
May 10, 2021
-
BUSINESS Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players
April 30, 2021
-
REGULATORY MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
-
BUSINESS Takeda, Eisai, Chemiphar Ran Early Retirement Programs over Past Year: Survey
April 28, 2021
-
BUSINESS Boehringer’s Japan Pharma Sales Rise 3.1% in 2020 on Ofev, Jardiance
April 28, 2021
-
BUSINESS Novartis Offering Voluntary Redundancy for 3rd Consecutive Year, Targets Sales & Medical across Therapeutic Areas
April 27, 2021
-
REGULATORY LDP Team Adopts Proposals to Push Japan-Made COVID-19 Vaccines, Urges Approval with Safety/Immunogenicity Studies
April 27, 2021
-
ACADEMIA New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
-
REGULATORY Olumiant Snags Japan Approval for COVID-19
April 23, 2021
-
BUSINESS Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
-
BUSINESS Supply Delays Likely for 160 Nichi-Iko Products despite Biz Suspension Lifted
April 22, 2021
-
REGULATORY Olumiant Now in Line for Japan Nod for COVID-19 Pneumonia
April 22, 2021
-
BUSINESS MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…